EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma

Antonio Omuro iD, Lisa M DeAngelis, Mei-Yin C Polley, Denise Correa, Jeffrey S Wefel, Joseph A Bovi, Marc Rosenblum, Benjamin W Corn, Sanjay Aneja, Christian Grommes, David M Peereboom, Enrico C Lallana und 8 weitere

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noaf221 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Antonio Omuro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA (A.O.). Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Neoplasms, Cranial Irradiation, Chemoradiotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institute of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methotrexate-based chemoradiotherapy is effective in primary central nervous system lymphoma (PCNSL) but carries a risk of severe neurotoxicity. In a single-arm study, a regimen with methotrexate, procarbazine, vincristine, and cytarabine was combined with rituximab (R-MPV-A) and substantially reduced doses of whole-brain radiotherapy (LD-WBRT), resulting in excellent progression-free survival (PFS) and overall survival (OS). Because R-MPV-A had never been tested without radiation, we sought to evaluate the efficacy of R-MPV-A with and without LD-WBRT, as well as determining if such low radiotherapy doses influenced disease control and/or neurotoxicity.

Methods

Patients were randomized to receive R-MPV-A alone (Chemo arm) or combined with LD-WBRT (ChemoRT arm), given at 2,340 cGy (180cGy X13). Primary endpoint was intent-to-treat (ITT) PFS. A sample size of 89 would provide 80% power to detect a hazard ratio (HR) of 0.63 (one-sided alpha = 0.15).

Results

Ninety-one patients were randomized, with 44 analyzed in the ChemoRT and 46 in the Chemo arm. Median age was 66 and 59.5, respectively. R-MPV-A was well tolerated, achieving a complete response rate of 92.3% (ChemoRT) and 76.3% (Chemo). After median follow-up of 4.6 years, median PFS was not reached (ChemoRT) vs 2.1 years (Chemo), HR = 0.47 (P = .007; 95% CI, 0.26-0.87). The 2-year PFS was 78.7% vs 54%, respectively. Differences in OS did not reach statistical significance (HR = 0.71; P = .33). Neuropsychological evaluation showed no differences in cognitive outcomes, with several tests favoring ChemoRT.

Conclusions

R-MPV-A is a highly efficacious and safe regimen with or without LD-WBRT. LD-WBRT contributes to disease control and increases PFS in PCNSL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCranial IrradiationChemoradiotherapyLymphomaImmunotherapyHumansFemaleMaleMiddle AgedRituximabAgedAdultMethotrexateVincristineFollow-Up StudiesSurvival RateProcarbazineCytarabinePrognosis

Stichwörter der Autor:innen

brain neoplasmchemotherapyclinical trialprimary central nervous system lymphomaradiotherapy

Substanzen

RituximabMethotrexateVincristineProcarbazineCytarabine

Autor:innen und Institutionen

  • Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA (A.O.).
  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA (L.M.D., D.C., M.R., C.G.).
  • NRG Oncology Statistics and Data Management Center, Chicago, IL, USA (M.-Y.C.P.).
  • Department of Public Health Sciences, University of Chicago, Chicago, IL, USA (M.-Y.C.P.).
  • Department of Neurology, University of Texas MD Anderson Cancer Center, Houston, TX, USA (J.S.W.).
  • Department of Radiation Oncology, ThedaCare Regional Cancer Center, Appleton, WI, USA (J.A.B.).

ORCID-Profile: Antonio Omuro, Minesh P Mehta

Förderung

  • NCI NIH HHS
  • National Institute of Health
  • National Cancer Institute

Zitieren

APA

Omuro, A., DeAngelis, L. M., Polley, M. C., Correa, D., Wefel, J. S., Bovi, J. A., Rosenblum, M., Corn, B. W., Aneja, S., Grommes, C., Peereboom, D. M., Lallana, E. C., Werner-Wasik, M., Rogers, C. L., Iwamoto, F. M., Yu, H. M., Donnelly, E. D., Struve, T. D., Won, M., & Mehta, M. P. (2026). Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf221

Vancouver

Omuro A, DeAngelis LM, Polley MC, Correa D, Wefel JS, Bovi JA, et al. Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf221

BibTeX
@article{Omuro2026,
  author = {Omuro, Antonio and DeAngelis, Lisa M and Polley, Mei-Yin C and Correa, Denise and Wefel, Jeffrey S and Bovi, Joseph A and Rosenblum, Marc and Corn, Benjamin W and Aneja, Sanjay and Grommes, Christian and Peereboom, David M and Lallana, Enrico C and Werner-Wasik, Maria and Rogers, C Leland and Iwamoto, Fabio M and Yu, Hsiang-Hsuan Michael and Donnelly, Eric D and Struve, Timothy D and Won, Minhee and Mehta, Minesh P},
  title = {Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noaf221}
}
Kostenlos starten →